Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis and Microsoft team up to develop intelligent camera system for MS

Novartis has been riding a med tech wave lately, launching new projects to create digital and patient-monitoring devices. In its latest move, the company is working with tech giant Microsoft to develop an intelligent camera system for multiple sclerosis (MS).

Novartis signs with France's MedinCell for controlled-release injection tech

French drug delivery specialist MedinCell is teaming up with Novartis' generic division Sandoz to develop controlled-release drugs with a focus on cancer.

Docs take aim at Novartis' 'horrifying' Entresto ad

It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' recently launched heart failure push is doing just that--literally and figuratively.

Doctors pounce on 'alarmist,' 'horrifying' Novartis heart-failure ad

It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' recently launched heart failure push is doing just that--literally and figuratively.

Pfizer keeps pushing on early hit Ibrance as Novartis, Lilly rivals near market

Pfizer's Ibrance has been steamrolling since it nabbed an early FDA go-ahead last February. And even with competition coming up the pipeline from the company's Big Pharma rivals, Pfizer intends to keep it that way.

With all eyes on Alcon, Novartis plots DTC ad push, new marketing spend

Novartis CEO Joe Jimenez is putting his faith in advertising. As part of a plan for turning around its Alcon unit, the Swiss drugmaker is mounting an aggressive consumer marketing push for its struggling contact lens business.

Don't blame industry trends for Sandoz's slide, analyst says. But biosimilars? Maybe

Last week, Novartis' Sandoz unveiled weak numbers, blaming them on broader generics-industry trends. But at least one analyst isn't convinced that's the culprit.

Novartis braces for multibillion-dollar generics hit as Gleevec copies launch

It's a dark day at Novartis. Sun Pharma rolled out its copycat version of Novartis' blockbuster cancer drug Gleevec, setting the Swiss drugmaker up for a big hit to 2016 sales.

New approvals, DTC put Novartis' Cosentyx on track to impress in 2016, pharma chief predicts

Industry watchers already have high expectations for Novartis' Cosentyx. But the company's execs think the drug--armed with two new approvals in quickly expanding markets--is on pace to exceed them in 2016.

Novartis retrains Entresto reps, plans field force expansion as payers finally step up

Novartis doesn't mind saying that Entresto fell short in the fourth quarter. The hotly anticipated heart drug brought in a paltry $5 million, not much given its impressive study data. But the Swiss drugmaker says Entresto is about to make an upward turn, and it's pushing hard to make sure that happens.